

Supplemental data for

**Estimating seroprevalence of SARS-CoV-2 infection after a highly contagious
Omicron outbreak: A cross sectional study in a university setting**

Ching-Wen Hou¹, Stacy Williams¹, Guillermo Trivino-Soto¹, Veronica Boyle¹, David Rainford¹, Selina Vicino¹, Mitch Magee¹, Yunro Chung^{1,2}, Joshua LaBaer¹, Vel Murugan^{1*}

¹Virginia G. Piper Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA

²College of Health Solutions, Arizona State University, Phoenix, AZ, USA

*Corresponding author. Email: vel.murugan@asu.edu

Supplementary Table 1: Anti-RBD and Anti-NC antibody seroprevalence status of the population from Serosurvey II

Antigen Detected	Ab Sub-Type	Manufacturer	Name of the test	Assay type	Positives	Negative	Inconclusive
RBD	IgG	Beckman Coulter	Access SARS-CoV-2 IgG II	Chemiluminescent Immunoassay (CLA)	1346 (96.3%)	51 (3.7%)	0 (0%)
		MSD	V-PLEX COVID-19 Respiratory Panel 3 Kit	Electrochemiluminescent immunoassay (ECL)	1369 (98%)	28 (2%)	0 (0%)
	IgM	Beckman Coulter	Access SARS-CoV-2 IgM	Chemiluminescent Immunoassay (CLA)	28 (2%)	1369 (98%)	0 (0%)
NC	IgG	MSD	V-PLEX COVID-19 Respiratory Panel 3 Kit	Electrochemiluminescent immunoassay (ECL)	578 (41.4%)	819 (58.6%)	0 (0%)
	Total Ab	Bio-Rad	Platelia SARS-CoV-2 Total Ab Assay	Enzyme-Linked Immunosorbent Assay (ELISA)	546 (39.1%)	823 (58.9%)	28 (2%)

Supplementary Table 2: Cohort characteristics and serological positive results by different assays from Serosurvey II

Cohort			Spike Protein		Nucleocapsid Protein	
Infection	Vaccine	n	IgG		Total ab	IgG
			Beckman	MSD	ELISA	MSD
Yes (n=529)	YES ^A	491	488 (99.4%)	484 (98.6%)	348 (70.9%)	352 (71.7%)
	YES ^B	4	4 (100%)	3 (75%)	4 (100%)	4 (100%)
	YES*	3	3 (100%)	3 (100%)	3 (100%)	3 (100%)
	NO	30	21 (70%)	24 (80%)	25 (83.3%)	25 (83.3%)
	NA	1	1 (100%)	1 (100%)	1 (100%)	1 (100%)
No (n=853)	YES ^A	805	781 (97%)	799 (99.3%)	133 (16.5%)	160 (19.9%)
	YES ^B	12	11 (91.7%)	10 (83.3%)	10 (83.3%)	10 (83.3%)
	YES*	3	3 (100%)	3 (100%)	2 (66.7%)	2 (66.7%)
	NO	31	18 (58.1%)	26 (83.9%)	12 (38.7%)	13 (41.9%)
	NA	2	1 (50%)	1 (50%)	0	0
(n=15)	YES	5	5 (100%)	5 (100%)	2 (40%)	2 (40%)
	NA	10	10 (100%)	10 (100%)	6 (60%)	6 (60%)
Total			1346 (96.3%)	1369 (98%)	546 (39.1%)	578 (41.4%)

A: Pfizer, Moderna, AstraZeneca, and Janssen; B: Covaxin, Sinopharm, *: Participants did not provide vaccine source

Supplementary Table 3: Seroconversion by race, age, gender, employment status, and the types of vaccines from Serosurvey II (Bold indicates statistically significant differences)

Variable	Comparison	Anti-RBD Antibody (Access SARS-CoV-2 IgG II)				Anti-NC antibody (Platelia NC total Ab)			
		n	OR	95% CI	P-value	n	OR	95% CI	P-value
Race	White vs Other	569 vs 289	0.98	(0.26, 3.08)	0.97	218 vs 147	0.55	(0.33, 0.91)	0.02
	Asian vs Other	355 vs 289	0.58	(0.15, 1.86)	0.38	144 vs 147	1.11	(0.60, 2.06)	0.73
	White vs Asian	569 vs 355	1.69	(0.59, 4.89)	0.33	218 vs 144	0.50	(0.28, 0.88)	0.02
Age	20-30 vs <20	584 vs 162	0.31	(0.02, 1.58)	0.26	264 vs 71	0.73	(0.36, 1.40)	0.36
	30-40 vs <20	187 vs 162	0.40	(0.02, 3.74)	0.46	79 vs 71	0.44	(0.18, 1.02)	0.06
	40-50 vs <20	123 vs 162	0.14	(0.01, 1.24)	0.12	37 vs 71	1.08	(0.34, 3.51)	0.90
	50>= vs <20	157 vs 162	0.50	(0.02, 6.84)	0.62	58 vs 71	0.81	(0.28, 2.30)	0.70
	30-40 vs 20-30	187 vs 584	1.31	(0.34, 6.59)	0.72	79 vs 264	0.60	(0.31, 1.15)	0.12
	40-50 vs 20-30	123 vs 584	0.46	(0.10, 2.02)	0.30	37 vs 264	1.47	(0.56, 4.15)	0.44
	50>= vs 20-30	157 vs 584	1.64	(0.27, 13.17)	0.60	58 vs 264	1.11	(0.48, 2.63)	0.81
	40-50 vs 30-40	123 vs 187	0.35	(0.07, 1.52)	0.17	37 vs 79	2.47	(1.00, 6.60)	0.06
	50>= vs 30-40	157 vs 187	1.25	(0.19, 9.94)	0.81	58 vs 79	1.86	(0.86, 4.11)	0.12
	50>= vs 40-50	157 vs 123	3.60	(0.75, 25.54)	0.13	58 vs 37	0.76	(0.27, 1.99)	0.58
Gender	Male vs Female	509 vs 704	0.78	(0.33, 1.85)	0.57	216 vs 293	0.83	(0.54, 1.27)	0.39
Employment Status	Student vs Employee	728 vs 485	1.84	(0.47, 6.50)	0.36	325 vs 184	0.94	(0.49, 1.77)	0.84
Vaccine Group [#]	mRNA vaccine vs Other vaccine	1020 vs 193	3.35	(1.20, 9.29)	0.02	381 vs 95	0.58	(0.30, 1.07)	0.09
	Unvaccinated vs Other vaccine	N/A	N/A	N/A	N/A	33 vs 95	1.43	(0.48, 4.86)	0.54
	mRNA vaccine vs Unvaccinated	N/A	N/A	N/A	N/A	381 vs 33	0.40	(0.13, 1.01)	0.07

#Unvaccinated samples were not included for the anti-RBD Antibody (Access SARS-CoV-2 IgG II)

Supplementary Table 4: Anti-RBD antibody difference by race, age, gender, employment status, and the types of vaccines controlling for days post vaccination from Serosurvey II (Bold indicates statistically significant differences)

Variable	Comparison				
		n	beta	95% CI	P-value
Race	White vs Other	569 vs 289	-25.04	(-62.28, 12.20)	0.19
	Asian vs Other	355 vs 289	-7.37	(-48.57, 33.82)	0.73
	White vs Asian	569 vs 355	-17.66	(-55.56, 20.23)	0.36
Age	20-30 vs <20	584 vs 162	-10.65	(-55.61, 34.30)	0.64
	30-40 vs <20	187 vs 162	-36.71	(-97.60, 24.19)	0.24
	40-50 vs <20	123 vs 162	-54.95	(-127.47, 17.57)	0.14
	50>= vs <20	157 vs 162	30.89	(-40.55, 102.34)	0.40
	30-40 vs 20-30	187 vs 584	-26.05	(-73.81, 21.71)	0.29
	40-50 vs 20-30	123 vs 584	-44.30	(-105.21, 16.62)	0.15
	50>= vs 20-30	157 vs 584	41.55	(-17.52, 100.61)	0.17
	40-50 vs 30-40	123 vs 187	-18.24	(-77.34, 40.85)	0.55
	50>= vs 30-40	157 vs 187	67.60	(11.64, 123.56)	0.02
	50>= vs 40-50	157 vs 123	85.85	(25.98, 145.71)	<0.01
Sex	Male vs Female	509 vs 704	18.02	(-12.16, 48.20)	0.24
Employment Status	Student vs Employee	728 vs 485	0.41	(-44.91, 45.72)	0.99
Vaccine Group	mRNA vaccine vs Other	1020 vs 193	129.71	(86.79, 172.63)	<0.001

Supplementary Table 5: Seroconversion by race, age, gender, employment status, and the types of vaccines from Serosurvey I and II (Bold indicates statistically significant differences)

Variable	Comparison	Anti- RBD Antibody (Access SARS-CoV-2 IgG II)				Anti- NC antibody (Platelia NC total Ab)			
		n	OR	95% CI	P-value	n	OR	95% CI	P-value
Race	White vs Other	855 vs 388	0.73	(0.34, 1.47)	0.40	291 vs 167	0.53	(0.34, 0.81)	<0.01
	Asian vs Other	495 vs 388	0.77	(0.35, 1.62)	0.51	156 vs 167	1.31	(0.76, 2.25)	0.33
	White vs Asian	855 vs 495	0.94	(0.51, 1.74)	0.85	291 vs 156	0.40	(0.24, 0.66)	<0.001
Age	20-30 vs <20	854 vs 343	1.25	(0.63, 2.35)	0.51	324 vs 102	0.78	(0.46, 1.28)	0.33
	30-40 vs <20	226 vs 343	0.92	(0.34, 2.70)	0.87	83 vs 102	0.51	(0.24, 1.04)	0.07
	40-50 vs <20	144 vs 343	0.36	(0.11, 1.31)	0.11	44 vs 102	1.00	(0.39, 2.67)	1.00
	50>= vs <20	171 vs 343	0.87	(0.21, 4.00)	0.85	61 vs 102	0.94	(0.39, 2.29)	0.89
	30-40 vs 20-30	226 vs 854	0.74	(0.31, 2.00)	0.52	83 vs 324	0.65	(0.36, 1.18)	0.16
	40-50 vs 20-30	144 vs 854	0.29	(0.09, 0.97)	0.04	44 vs 324	1.29	(0.56, 3.13)	0.56
	50>= vs 20-30	171 vs 854	0.70	(0.18, 3.01)	0.61	61 vs 324	1.21	(0.56, 2.65)	0.63
	40-50 vs 30-40	144 vs 226	0.40	(0.12, 1.29)	0.12	44 vs 83	1.98	(0.87, 4.72)	0.11
	50>= vs 30-40	171 vs 226	0.94	(0.24, 3.98)	0.93	61 vs 83	1.85	(0.89, 3.96)	0.11
	50>= vs 40-50	171 vs 144	2.38	(0.69, 9.37)	0.18	61 vs 44	0.94	(0.38, 2.27)	0.89
Gender	Male vs Female	759 vs 979	0.90	(0.53, 1.52)	0.70	274 vs 340	0.93	(0.64, 1.34)	0.69
Employment Status	Student vs Employee	1209 vs 529	0.75	(0.28, 1.88)	0.55	422 vs 192	0.76	(0.43, 1.33)	0.34
Vaccine Group [#]	mRNA vaccine vs Other	1465 vs 273	8.11	(4.60, 14.56)	<0.001	455 vs 115	1.03	(0.62, 1.69)	0.89
	Unvaccinated vs Other vaccine	N/A	N/A	N/A	N/A	44 vs 115	1.81	(0.79, 4.40)	0.17
	mRNA vaccine vs Unvaccinated	N/A	N/A	N/A	N/A	455 vs 44	0.57	(0.26, 1.17)	0.14


#Unvaccinated samples were not included for the anti-RBD Antibody (Access SARS-CoV-2 IgG II)

Supplementary Table 6: Anti-RBD antibody difference by race, age, gender, employment status, and the types of vaccines controlling for days post vaccination from Serosurvey I and II (Bold indicates statistically significant differences)

Variable	Comparison				
		n	beta	95% CI	P-value
Race	White vs Other	855 vs 388	-34.22	(-60.90, -7.53)	0.01
	Asian vs Other	495 vs 388	-20.37	(-50.70, 9.95)	0.19
	White vs Asian	855 vs 495	-13.84	(-40.26, 12.57)	0.30
Age	20-30 vs <20	854 vs 343	-13.70	(-41.88, 14.48)	0.34
	30-40 vs <20	226 vs 343	-37.13	(-79.31, 5.05)	0.08
	40-50 vs <20	144 vs 343	-64.39	(-116.87, -11.92)	0.02
	50>= vs <20	171 vs 343	18.61	(-33.51, 70.73)	0.48
	30-40 vs 20-30	226 vs 854	-23.43	(-59.59, 12.72)	0.20
	40-50 vs 20-30	144 vs 854	-50.70	(-97.90, -3.50)	0.04
	50>= vs 20-30	171 vs 854	32.31	(-14.11, 78.72)	0.17
	40-50 vs 30-40	144 vs 226	-27.26	(-74.31, 19.78)	0.26
	50>= vs 30-40	171 vs 226	55.74	(10.38, 101.10)	0.02
	50>= vs 40-50	171 vs 144	83.00	(34.38, 131.63)	<0.001
Sex	Male vs Female	759 vs 979	17.28	(-4.38, 38.93)	0.12
Employment Status	Student vs Employee	1209 vs 529	-17.25	(-52.72, 18.21)	0.34
Vaccine Group	mRNA vaccine vs Other	1465 vs 273	97.24	(67.06, 127.42)	<0.001

Supplementary Table 7: The comparison of key outcome variables between the two serosurveys

Serosurvey	I	II
Study Dates	9/13-9/17, 2021	3/1-3/3,2022
% Vaccinated (self-reported)	91.9%	94.7%
% Infected (self-reported)	19.3%	37.9%
% of positive result of anti-RBD IgG	88.2% (Beckman) 97% (MSD)	96.3% (Beckman) 98% (MSD)
% of positive result of anti-N	19.7% (Bio-Rad) 16.1% (MSD)	39.1% (Bio-Rad) 41.4 % (MSD)
% Unknown infection	8.9% (Bio-Rad) 9.4% (MSD)	16.5% (Bio-Rad) 19.9% (MSD)



Supplementary Figure 1: Median level of antibody levels of different variants using MSD assay. Anti-RBD antibodies were measured using different variants of antigens with the MSD platform. *P value is calculated by the Mann-Whitney test. *p-value <0.05, **p-value <0.01, ***p-value <0.001 and ****p-value <0.0001.